COVID‐19, hypertension, and renin‐angiotensin‐aldosterone system inhibitors: Much ado about nothing or real problem to be solved?

Saved in:
Bibliographic Details
Published inThe journal of clinical hypertension (Greenwich, Conn.) Vol. 22; no. 11; pp. 1984 - 1986
Main Authors Tadic, Marijana, Cuspidi, Cesare
Format Journal Article
LanguageEnglish
Published United States John Wiley and Sons Inc 01.11.2020
Subjects
Angiotensin Receptor Antagonists - adverse effects
Angiotensin Receptor Antagonists - therapeutic use
Angiotensin-Converting Enzyme Inhibitors - adverse effects
Angiotensin-Converting Enzyme Inhibitors - therapeutic use
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
COVID-19 - diagnosis
COVID-19 - epidemiology
COVID-19 - mortality
COVID-19 - virology
Covid‐19
Hospitalization - statistics & numerical data
Humans
Hypertension - complications
Hypertension - drug therapy
Hypertension - epidemiology
Hypertension - mortality
Intensive Care Units - statistics & numerical data
Prevalence
Renin-Angiotensin System - drug effects
Respiration, Artificial - statistics & numerical data
Respiratory Distress Syndrome - epidemiology
Respiratory Insufficiency - epidemiology
Risk Factors
SARS-CoV-2 - drug effects
SARS-CoV-2 - genetics
Severity of Illness Index
Shock, Septic - epidemiology
Online AccessGet full text
ISSN1524-6175
1751-7176
1751-7176
DOI10.1111/jch.14045

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1524-6175
1751-7176
1751-7176
DOI:10.1111/jch.14045